.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,966,891

« Back to Dashboard

Claims for Patent: 4,966,891

Title: Fluorocytidine derivatives
Abstract:The novel 5'-deoxy-5-fluorocytidine derivatives of formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are hydrogen or an easily hydrolyzable radical under physiological conditions, with the proviso that, at least one or R.sup.1, R.sup.2 and R.sup.3 is an easily hydrolyzable radical under physiological conditions, as well as hydrates of solvates of these compounds have antitumor properties. They can be prepared from compounds of formula I, wherein R.sup.1 is hydrogen or an amino-protecting radical and R.sup.2 and R.sup.3 are hydrogen or a hydroxy-protecting radical or taken together are a cyclic hydroxy-protecting radical.
Inventor(s): Fujiu; Morio (Chigasaki, JP), Ishitsuka; Hideo (Yokohama, JP), Miwa; Masanori (Kamakura, JP), Umeda; Isao (Yokohama, JP), Yokose; Kazuteru (Urayasu, JP)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:07/268,437
Patent Claims: 1. A compound of the formula: ##STR43## wherein R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen, or an easily hydrolyzable radical under physiological conditions, with the proviso that, at least one of R.sup.1, R.sup.2, or R.sup.3 is an easily hydrolyzable radical under physiological conditions;

as well as hydrates or solvates of the compounds of the general formula (I).

2. The compound of claim 1 wherein the easily hydrolyzable radical is selected from the group consisting of

wherein R.sup.4 represents hydrogen, alkyl, cycloalkyl, oxoalkyl, alkenyl, aralkyl or aryl; R.sup.5 is alkyl or aralkyl radical; and R.sup.6 is alkyl or aralkyl.

3. A compound selected from the group consisting of:

N.sup.4 -acetyl-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -propionylcytidine,

N.sup.4 -butyryl-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -isobutyrylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-methylbutyryl)cytidine,

5'-deoxy-N.sup.4 -(2-ethylbutyryl)-5-fluorocytidine,

5'-deoxy-N.sup.4 -(3,3-dimethylbutyryl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -pivaloylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -valerylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -isovalerylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-methylvaleryl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3-methylvaleryl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-methylvaleryl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -hexanoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -heptanoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -octanoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -nonanoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -hexadecanoylcytidine,

N.sup.4 -benzoyl-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-methylbenzoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3-methylbenzoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-methylbenzoyl)cytidine,

5'-deoxy-N.sup.4 -(4-ethylbenzoyl)-5-fluorocytidine,

5'-deoxy-N.sup.4 -(3,4-dimethylbenzoyl)-5-fluorocytidine,

5'-deoxy-N.sup.4 -(3,5-dimethylbenzoyl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-methoxybezoyl)cytidine,

5'-deoxy-N.sup.4 -(3,4-dimethoxybenzoyl)-5-fluorocytidine,

5'-deoxy-N.sup.4 -(3,5-dimethoxybenzoyl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3,4,5-trimethoxybenzoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3,4,5-triethoxybenzoyl)cytidine,

5'-deoxy-N.sup.4 -(4-ethoxybenzoyl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-propoxybenzoyl)cytidine,

5'-deoxy-N.sup.4 -(3,5-diethoxybenzoyl)-5-fluorocytidine,

N.sup.4 -(4-chlorobenzoyl)-5'-deoxy-5-fluorocytidine,

' -deoxy-N.sup.4 -(3,4-dichlorobenzoyl)-5-fluorocytidine,

5'-deoxy-N.sup.4 -(3,5-dichlorobenzoyl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-nitrobenzoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-methoxycarbonylbenzoyl)cytidine,

N.sup.4 -(4-acetylbenzoyl)-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(phenylacetyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-methoxyphenylacetyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -nicotinoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -isonicotinoylcytidine

5'-deoxy-5-fluoro-N.sup.4 -picolinoylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-furoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(5-nitro-2-furoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-thenoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(5-methyl-2-thenoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(1-methyl-2-pyrrolecarbonyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3-indolylacetyl)cytidine,

N.sup.4 -(3-butenoyl)-5'-deoxy-5-fluorocytidine,

3'-0-benzoyl-5'-deoxy-5-fluorocytidine,

N.sup.4,3'-0-dibenzoyl-5'-deoxy-5-fluorocytidine and

5'-deoxy-N.sup.4 -(ethylthio)carbonyl-5-fluorocytidine.

4. A compound of claim 2 selected from the group consisting of:

5'-deoxy-5-fluoro-N.sup.4 -octadecanoylcytidine,

N.sup.4 -cyclopropanecarbonyl-5'-deoxy-5-fluorocytidine,

N.sup.4 -cyclohexanecarbonyl-5'-deoxy-5-fluorocytidine,

N.sup.4 -(1-adamantanecarbonyl)-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-methoxybenzoyl)cytidine,

5'-deoxy-N.sup.4 -(2,4-dimethoxybenzoyl)-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -piperonyloylcytidine,

5'-deoxy-5-fluoro-N.sup.4 -(4-fluorobenzoyl)cytidine,

N.sup.4 -(2-chlorobenzoyl)-5'-deoxy-5-fluorocytidine,

N.sup.4 -(3-chlorobenzoyl)-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3-nitrobenzoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -[4-(methylthio)benzoyl]cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(2-naphthoyl)cytidine,

' -deoxy-5-fluoro-N.sup.4 -(3-furoyl)cytidine,

5'-deoxy-5-fluoro-N.sup.4 -(3-phenylpropionyl)cytidine,

N.sup.4 -cinnamoyl-5'-deoxy-5-fluorocytidine,

2',3'-di-0-benzoyl-5'-deoxy-5-fluorocytidine,

N.sup.4,2'-0,3'-0-tribenzoyl-5'-deoxy-5-fluorocytidine,

5'-deoxy-5-fluoro-N.sup.4 -(octyloxycarbonyl)cytidine,

N.sup.4 -(benzyloxycarbonyl)-5'-deoxy-5-fluorocytidine and

5'-deoxy-5-fluoro-N.sup.4 -formylcytidine.

5. A method for inhibiting the growth of sarcoma, fibrosarcoma, or carcinoma in a subject comprising administering to the subject an antitumor effective amount of the compound of Formula I or the hydrates and solvates thereof.

6. A method for the manufacture of the compound of Formula I comprising reacting a compound of the formula ##STR44## wherein R.sup.7 represents hydrogen or an amino-protecting radical; R.sup.8 and R.sup.9 are each independently hydrogen, or a hydroxy-protecting group; or R.sup.8 and R.sup.9, taken together, form a cyclic hydroxy-protecting group,

with a compound of the formula

wherein X is a leaving radical and R.sup.4 is hydrogen, alkyl, cycloalkyl, oxoalkyl, alkenyl, aralkyl, or aryl;

or with a compound of the formula

wherein Y is halogen and R.sup.10 is a radical of the formula,

wherein R.sup.5 is alkyl or aralkyl, and R.sup.6 is alkyl or aralkyl;

followed, if necessary, by removal of a protecting radical.

7. A pharmaceutical composition with antisarcoma, antifibrosarcoma, or anticarinoma activity comprised of an therapeutically effective amount of a compound of Formula I as the active ingredient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc